Company news

Dianthus Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145 Phase 1 Results and Update on Targeted ADC Conditioning Program MGTA-117 at ASH Annual Meeting

December 6, 2020

Magenta Therapeutics Appoints Steve Mahoney as Chief Financial and Operating Officer

November 8, 2020

Magenta Therapeutics Reports Recent Business Highlights and Third Quarter Financial Results

November 4, 2020

Magenta Therapeutics Announces Multiple Presentations Across Stem Cell Transplant Portfolio at The American Society of Hematology (ASH) Annual Meeting

November 3, 2020

Magenta Therapeutics Named Co-Recipient of Grant from the National Institutes of Health to Explore Use of Novel Targeted Conditioning Agents with Gene Editing Approaches to Cure HIV

September 1, 2020

Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality; Announces Transition of Jason Ryan, Chief Operating and Financial Officer

September 1, 2020

Magenta Therapeutics Announced It Will Present Clinical and Pre-Clinical Data from Across Immune and Blood System Reset Portfolio at European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting

August 30, 2020

Magenta Therapeutics Reports Recent Business Highlights and Second Quarter Financial Results

August 5, 2020

Magenta Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

June 29, 2020

Magenta Therapeutics Launches Proposed Public Offering

June 23, 2020

Magenta Therapeutics Announces Pricing of Public Offering

June 23, 2020

Magenta Therapeutics Announces Collaboration with the National Marrow Donor Program/Be The Match to Advance Development of MGTA-145 for First-Line Mobilization of Stem Cells from Healthy Donors and Subsequent Patient Transplant

June 10, 2020

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences

June 7, 2020

Magenta Therapeutics Presents Data at Annual Meeting of American Society of Gene and Cell Therapy Demonstrating Cells Mobilized with MGTA-145 in a Phase I Trial Are Effective in Gene Therapy Settings

May 13, 2020

Magenta Therapeutics Reports Recent Business Highlights and First Quarter Financial Results

May 6, 2020

Magenta Therapeutics to Host Business Update Conference Call

April 29, 2020

Magenta Therapeutics to Present Data from Across Portfolio at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

April 27, 2020

Magenta Therapeutics Names John Davis Jr., M.D., M.P.H, M.S., Head of Research and Development

April 16, 2020

Magenta Therapeutics Provides Business Update

April 15, 2020

Magenta Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

March 2, 2020

Magenta Therapeutics to Participate in Cowen Health Care Conference on Monday, March 2nd in Boston

February 25, 2020

Magenta Therapeutics Completes Dosing in Phase 1 MGTA-145 Trial, Demonstrating Rapid, Single-Day First Line Stem Cell Mobilization and Collection

February 23, 2020

Magenta Therapeutics Announces Updated Phase 2 Data on MGTA-456 Cell Therapy, Demonstrating Continued Durability in Inherited Metabolic Disorders

February 19, 2020

Magenta Therapeutics to Participate in Guggenheim Healthcare Talks Oncology Day on Thursday, February 13th in New York City

February 5, 2020

Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals

January 12, 2020

Magenta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th in San Francisco

January 5, 2020

Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug Conjugate

December 8, 2019

Magenta Therapeutics to Present at the Evercore ISI HealthCONx Conference on Tuesday, December 3rd

November 25, 2019

Magenta Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

November 12, 2019

Magenta Therapeutics Presents First Immune Reset Results with Antibody-Drug Conjugate Across Multiple Autoimmune Diseases at ACR

November 10, 2019

Magenta Therapeutics to Present New Clinical and Preclinical Data at American Society of Hematology (ASH) Annual Meeting

November 5, 2019

Magenta Therapeutics Appoints Jan Pinkas as Senior Vice President, Head of Translational Sciences and Announces Transition of Chief Scientific Officer

October 15, 2019

← Newer news releases

Decks

The 5 newest of 18 decks. Every deck is listed under its year.